Jefferies将Krystal生物科技的价格目标提高至371美元, Jefferies raises Krystal Biotech's price target to $371, citing progress in gene therapy for rare skin diseases.

Jefferies将Krystal Biotech的股票价格目标提高到371美元, Krystal Biotech's stock price target was raised to $371 by Jefferies, which maintained a "Buy" rating, citing strong progress in its gene therapy pipeline for rare skin diseases. 该公司的主要候选人KRT-100在治疗上层血解牛群方面表现出了希望,积极的临床发展提高了投资者的信心。 The company's lead candidate, KRT-100, shows promise in treating epidermolysis bullosa, and positive clinical developments have boosted investor confidence. 尽管对收入作了一些预测修订,但机构兴趣仍然很高,有坚实的金融手段和强有力的商业管道支持。 Despite some earnings forecast revisions, institutional interest remains high, supported by solid financials and a robust commercial pipeline. 股票交易额约为261.80美元,市场上限为76.5亿美元,其中86.29%的股份由机构持有。 The stock, trading around $261.80, has a market cap of $7.65 billion, with 86.29% of shares held by institutions.